Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303

BACKGROUND: Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet‐derived growth factor receptor, and stem cell factor receptor (c‐Kit). In the phase III ALTER‐0303 trial (Clinical Trial Registry ID: NCT 0238...

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Xiaoyan, Zhang, Li, Wang, Hanping, Zhang, Xiaotong, Wang, Mengzhao, Han, Baohui, Li, Kai, Wang, Qiming, Shi, Jianhua, Wang, Zhehai, Cheng, Ying, Shi, Yuankai, Chen, Weiqiang, Wang, Xiuwen, Luo, Yi, Nan, Kejun, Jin, Faguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397894/
https://www.ncbi.nlm.nih.gov/pubmed/30666799
http://dx.doi.org/10.1111/1759-7714.12977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397894/
https://www.ncbi.nlm.nih.gov/pubmed/30666799
http://dx.doi.org/10.1111/1759-7714.12977

Ejemplares similares